Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound glutamine is a combination drug composed of L-glutamine, a conditionally essential amino acid, and the traditional Chinese herbal formula Si-Jun-Zi-Tang. Si-Jun-Zi-Tang consists of ginseng, Atractylodes macrocephala, Poria cocos, and licorice. This drug has been widely used in China for 23 years to treat various gastrointestinal diseases, including gastrointestinal reactions induced by radiotherapy and chemotherapy, ulcerative colitis, and irritable bowel syndrome. Its mechanism involves L-glutamine's role in maintaining the integrity of the mucosal epithelium and supporting nitrogen balance, thereby reducing gastrointestinal side effects. It is currently being investigated for the primary prevention of chemotherapy-induced mucositis, radiation-induced oral mucositis, and in the treatment of ulcerative colitis and radiation proctitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound glutamine.